e-learning
resources
Berlin 2001
Tuesday 25.09.2001
Novel approaches to treatment of lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cluster immunotherapy. SR theophylline in prevention of systemic reactions
J. Matuska, M. Bajer (Brno, Czech Republic)
Source:
Annual Congress 2001 - Novel approaches to treatment of lung disease
Session:
Novel approaches to treatment of lung disease
Session type:
Thematic Poster Session
Number:
2897
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Matuska, M. Bajer (Brno, Czech Republic). Cluster immunotherapy. SR theophylline in prevention of systemic reactions. Eur Respir J 2001; 16: Suppl. 31, 2897
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004
Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012
Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy
vs
specific immunotherapy allone
Source: Eur Respir J 2001; 18: Suppl. 33, 431s
Year: 2001
Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments
Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Year: 2018
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005
Desensitization therapy for allergic reactions of antituberculous drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma
Source: Eur Respir J 2006; 28: 1042-1050
Year: 2006
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003
Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 385s
Year: 2002
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019
Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 62s
Year: 2004
Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Bronchial asthma as neurogenic paroxysmal inflammatory disease - high efficacy of antiepileptic drug oxcarbazepine in asthma monotherapy
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept